# Tarceva and Capecitabine for Pancreatic Cancer

> **NCT00125021** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 32 (actual)

## Conditions studied

- Pancreatic Cancer
- Neoplasm Metastasis

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** OSI-774

## Key facts

- **NCT ID:** NCT00125021
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2004-06
- **Final completion:** 2008-09
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2009-11-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00125021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00125021, "Tarceva and Capecitabine for Pancreatic Cancer". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT00125021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*